Franklin Biotechnology Discovery A
- FBDIX
- Price as of: Mar 04, 2021
-
$168.32
N/A N/A
- Primary Theme
- Health Care Sector Equity
- Fund Company
- Franklin Templeton
- Share Class
FBDIX - Snapshot
Vitals
- YTD Return -5.2%
- 3 Yr Annualized Return 13.4%
- 5 Yr Annualized Return 15.3%
- Net Assets $1.56 B
- Holdings in Top 10 45.7%
52 WEEK LOW AND HIGH
Expenses
OPERATING RELATED FEES
- Expense Ratio 1.03%
SALES FEES
- Front Load 5.50%
- Deferred Load N/A
BROKERAGE FEES
- Turnover 32.92%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $1,000
- IRA $250
Fund Classification
-
Primary Theme
Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
FBDIX - Profile
Distributions
- YTD Total Return -5.2%
- 3 Yr Annualized Total Return 11.2%
- 5 Yr Annualized Total Return 14.0%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.49%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameFranklin Biotechnology Discovery Fund
-
Fund Family NameFranklin Templeton Investments
-
Inception DateSep 15, 1997
-
Shares Outstanding7183289
-
Share ClassA
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerEvan McCulloch
Fund Description
Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
FBDIX - Performance
Return Ranking - Trailing
Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -5.2% | -8.7% | 16.9% | 85.47% |
1 Yr | 36.8% | 11.4% | 174.0% | 35.37% |
3 Yr | 13.4%* | 3.7% | 54.2% | 64.34% |
5 Yr | 15.3%* | 5.3% | 44.0% | 49.29% |
10 Yr | 17.3%* | 9.3% | 22.0% | 29.03% |
* Annualized
Return Ranking - Calendar
Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2020 | 13.6% | -13.6% | 178.2% | 54.04% |
2019 | 23.3% | 3.8% | 63.8% | 31.03% |
2018 | -18.6% | -49.7% | 21.5% | 91.24% |
2017 | 16.0% | -59.8% | 54.4% | 58.52% |
2016 | -20.7% | -36.6% | 11.6% | 78.29% |
Total Return Ranking - Trailing
Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -5.2% | -8.7% | 16.9% | 85.47% |
1 Yr | 29.3% | 5.6% | 174.0% | 58.54% |
3 Yr | 11.2%* | 2.6% | 54.2% | 81.82% |
5 Yr | 14.0%* | 4.8% | 44.0% | 61.43% |
10 Yr | 16.7%* | 9.3% | 22.0% | 37.10% |
* Annualized
Total Return Ranking - Calendar
Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2020 | 13.6% | -13.6% | 178.2% | 54.04% |
2019 | 23.3% | 3.8% | 63.8% | 31.03% |
2018 | -18.6% | -25.3% | 22.2% | 92.70% |
2017 | 18.8% | -10.8% | 54.4% | 61.48% |
2016 | -17.1% | -36.6% | 11.6% | 72.09% |
NAV & Total Return History
FBDIX - Holdings
Concentration Analysis
FBDIX | Category Low | Category High | FBDIX % Rank | |
---|---|---|---|---|
Net Assets | 1.56 B | 6.18 M | 47.2 B | 37.57% |
Number of Holdings | 106 | 25 | 452 | 41.62% |
Net Assets in Top 10 | 706 M | 1.55 M | 19.6 B | 30.64% |
Weighting of Top 10 | 45.68% | 11.9% | 77.2% | 23.12% |
Top 10 Holdings
- Gilead Sciences Inc 6.42%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
- Regeneron Pharmaceuticals Inc 6.06%
Asset Allocation
Weighting | Return Low | Return High | FBDIX % Rank | |
---|---|---|---|---|
Stocks | 95.49% | 82.92% | 104.32% | 87.28% |
Cash | 4.25% | -0.24% | 11.60% | 8.09% |
Preferred Stocks | 0.27% | 0.00% | 5.23% | 6.94% |
Other | 0.00% | -27.80% | 10.48% | 52.02% |
Convertible Bonds | 0.00% | 0.00% | 0.02% | 40.46% |
Bonds | 0.00% | 0.00% | 19.34% | 45.66% |
Stock Sector Breakdown
Weighting | Return Low | Return High | FBDIX % Rank | |
---|---|---|---|---|
Healthcare | 98.92% | 63.91% | 100.00% | 57.23% |
Financial Services | 1.08% | 0.00% | 4.05% | 10.98% |
Utilities | 0.00% | 0.00% | 0.03% | 39.88% |
Technology | 0.00% | 0.00% | 16.33% | 53.18% |
Real Estate | 0.00% | 0.00% | 5.95% | 45.09% |
Industrials | 0.00% | 0.00% | 4.84% | 46.24% |
Energy | 0.00% | 0.00% | 0.03% | 40.46% |
Communication Services | 0.00% | 0.00% | 13.83% | 43.35% |
Consumer Defense | 0.00% | 0.00% | 30.57% | 41.62% |
Consumer Cyclical | 0.00% | 0.00% | 11.81% | 45.66% |
Basic Materials | 0.00% | 0.00% | 3.50% | 57.80% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | FBDIX % Rank | |
---|---|---|---|---|
US | 84.00% | 58.03% | 100.01% | 45.09% |
Non US | 11.49% | 0.00% | 40.57% | 61.85% |
FBDIX - Expenses
Operational Fees
FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 1.03% | 0.08% | 25.14% | 50.60% |
Management Fee | 0.60% | 0.00% | 1.25% | 34.10% |
12b-1 Fee | 0.25% | 0.00% | 1.00% | 34.21% |
Administrative Fee | 0.15% | 0.03% | 0.25% | 73.81% |
Sales Fees
FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | 5.50% | 3.50% | 5.75% | 65.22% |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 32.92% | 0.70% | 252.00% | 29.27% |
FBDIX - Distributions
Dividend Yield Analysis
FBDIX | Category Low | Category High | FBDIX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 1.08% | 49.13% |
Dividend Distribution Analysis
FBDIX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annually | Annually | Annually | Annually |
Net Income Ratio Analysis
FBDIX | Category Low | Category High | FBDIX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.49% | -2.53% | 1.74% | 81.66% |
Capital Gain Distribution Analysis
FBDIX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Dividend Payout History
Date | Amount |
---|---|
Dec 19, 2016 | $1.728 |
Dec 19, 2012 | $0.069 |
Dec 30, 2011 | $0.515 |
FBDIX - Fund Manager Analysis
Managers
Evan McCulloch
Start Date
Tenure
Tenure Rank
Sep 15, 1997
23.47
23.5%
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Wendy Lam
Start Date
Tenure
Tenure Rank
Sep 01, 2018
2.5
2.5%
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Akiva Felt
Start Date
Tenure
Tenure Rank
Jan 27, 2020
1.09
1.1%
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.12 | 23.47 | 7.27 | 20.84 |